In this issue:
- First-line atezolizumab in platinum-ineligible NSCLC
- Perioperative pembrolizumab/ nivolumab for NSCLC
- Nivolumab-ipilimumab in advanced salivary gland cancer
- ICIs in metastatic uveal melanoma
- Selective immunosuppressants after treatment for ICI-induced colitis
- Real-world first-line pembrolizumab in advanced urothelial carcinoma
- First-line pembrolizumablenvatinib for advanced non-clear-cell RCC
- Worse OS after pre-ICI antibiotics in older cancer patients
- ICIs for Child-Pugh class B advanced HCC
- Trastuzumab deruxtecan for HER2+ advanced progressive gastric cancer
Please login below to download this issue (PDF)